Can Q2 sustain the margin momentum?
Alivus heads into Q2 reporting with strong FY27 guidance (10-12% growth, 30-34% EBITDA margin) and a stellar Q1 behind it. The Street expects steady revenue growth, but the real watch is whether EBITDA margin hold above 32% amid recent acquisitions and external headwinds.
What to watch: the Q2 margin test
Alivus Life Sciences (formerly Glenmark Life Sciences) delivered an impressive Q1 FY27: revenue ₹6,404 Mn (6.4% YoY), PAT ₹1,601 Mn (+32% YoY). The company guided for 10–12% FY27 revenue growth and EBITDA margins in the 30–32% range, with potential upside to 34%. Q2 will test whether this margin resilience holds as the company integrates two acquisitions (IQGenX Pharma in August, a 9.21% stake in Torrent Urja in October) and navigates currency volatility.
~₹6,400–6,500 Cr
Aligned with 10-12% FY27 guidance; Q1 was ₹6,404 Mn
30–32%
Guided range; Q1 likely exceeded lower bound; execution on non-GPL growth critical
TBD; Q1 was +32% YoY
Operating leverage + margin mix vs. recent acquisition costs will determine Q2 pace
Strong (₹5 dividend approved Aug '26)
Sustainability depends on Q2 profit; recent dividend payout signals confidence
Strong Q1, but H2 is the real test
Q1 was a beat — a 32% PAT surge on only 6.4% revenue growth points to significant margin expansion. The company flagged that growth is weighted toward H2 FY27, which means Q2 (Jul–Sep quarter) is likely to show sequential moderation in growth rate. A strong print would show: revenue tracking toward the 10-12% FY27 target (implying ~₹6,400–6,500 Cr for Q2), EBITDA margin ≥32%, and PAT growth sustaining double digits despite earlier-stage integration of IQGenX and the Torrent Urja investment. A weak print would reveal: revenue below ₹6,350 Cr, EBITDA margin slipping below 30%, or PAT growth decelerating sharply (sub-15% YoY), signaling either macro headwinds, currency stress, or integration drag.
Recent filings & corporate actions
1 · M&A integration: IQGenX & Torrent Urja
In August, Alivus acquired 76% of IQGenX Pharma (CRO, founded 2016) for ₹9.12 Cr. In October, it bought a 9.21% stake in Torrent Urja (renewable energy, ESG compliance) for ₹14.04 Cr. Both signal strategic diversification but will carry one-time costs. Watch Q2 for any drag on consolidated margins and interest expense uptick.
2 · GST notice: ₹51.22 Lakh demand (FY20-21, FY21-22)
October 9: Tax demand of ₹25.61 Lakh + ₹25.61 Lakh penalty. Material impact immaterial but flags exposure to regulatory action. No material impact on Q2 P&L expected.
3 · Dividend approved: ₹5 per share (Sep '26)
Final dividend for FY26 approved at AGM (Sep 8). Record date Sep 1, 2026. Payout ratio signals management confidence in cash flow. Watch Q2 for any comments on sustainable dividend.
4 · Brazil subsidiary incorporated (Sep '26)
Wholly-owned subsidiary Alivus Life Sciences Do Brasil Ltda. set up in Sao Paulo with R$5Mn authorized capital. Long-term play; no near-term P&L impact expected in Q2.
Key metrics: on track to guidance?
Revenue growth YoY
10–12%
Q2 needs to accelerate; on-plan would be 8–10% (rising toward H2)
6.4%
EBITDA margin
30–32% (range); 34% upside
Q1 likely beat guidance; Q2 margin hold above 32% is key watch
~33–34% (inferred)
PAT growth YoY
Unspecified; FY27 EPS target ₹55.90 (+14%)
Q1 beat implied FY27 growth rate; Q2 normalization expected
+32%
Three things to watch on Oct 29
1 · Does revenue track ₹6,400+ Cr?
Critical for the 10-12% FY27 growth thesis. Below ₹6,350 Cr would signal macro slowdown or pricing pressure in APIs. Guidance commentary on H2 momentum will matter more than Q2 absolute numbers.
2 · EBITDA margin: hold ≥32%?
Q1 likely exceeded the 30-32% range. Q2 is the test of durability: integration costs from IQGenX and Torrent Urja, forex headwinds, and mix shift (non-GPL business growth). Margin miss below 30% would be a red flag.
3 · Management commentary: H2 growth inflection
Company flagged that growth is skewed to H2. Listen for specifics: new API launches, customer wins, or demand visibility. If H2 caution emerges or acquisition integration drags, stock will react. Look for capex plans (Brazil, IQGenX capex) and impact on FY27 FCF.
Alivus Life Sciences is a well-positioned API compounder with strong margin profiles and a pipeline of growth drivers (non-GPL expansion, emerging markets, CRO integration). Q2 FY27 will test two things: (1) whether 10–12% revenue growth and 30–32% EBITDA margins are sustainable, or just Q1 noise, and (2) how much integration drag from recent M&A shows up in the P&L. Street consensus remains constructive (Buy, ₹1,432 target), but execution risk is real. Watch for margin hold and H2 guidance tone on October 29.
Informational and educational content only. Not investment advice.